Chris Pak

Company: Molecular Targeting Technologies

Job title: President & Chief executive officer

Seminars:

Overcoming TRP Challenges in GBM Therapy with an Albumin Binding Radiopharmaceutical 3:45 pm

Strategies to overcome common challenges of short-lived, rapidly clearing Targeted Radiopharmaceuticals (TRP) Transforming targeted radiotherapy with an Evans blue (EB) conjugate. EB binds to albumin, abundant in the blood, resulting in a longer circulatory half-life. Better tissue absorption, retention, and nephroprotection enhance the treatment Studies with EB-modified integrin binding peptide significantly improves pharmacokinetics of targeted…Read more

day: Conference Day 1